Pluristem Therapeutics (PSTI) Receives Israeli Ministry of Health Approval to Expand Its Phase 2 Clinical Trial in Intermittent Claudication to Israel
10/2/2013 9:48:17 AM
HAIFA, Israel, Oct. 2, 2013 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, announced today that the Israeli Ministry of Health has approved the company's request to initiate a Phase II study using its PLacental eXpanded (PLX) cells in the treatment of Intermittent Claudication (IC), a subset of peripheral artery disease (PAD). This approval is part of the company's previously announced strategy to conduct a multi-national study for this indication. The protocol will be the same one used for the study previously approved in the U.S.
Help employers find you! Check out all the jobs and post your resume.
comments powered by